Array BioPharma Inc. (NASDAQ:ARRY) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with -1.14% to $3.48. Array BioPharma (ARRY) released that the FDA has agreed its New Drug Application or NDA for binimetinib with a target action date under the Prescription Drug User Fee Act or PDUFA of June 30, 2017. Array completed its NDA submission of binimetinib in late June 2016 based on findings from the pivotal Phase 3 NEMO trial in patients with NRAS-mutant melanoma.
The FDA also indicated that it plans to hold an advisory committee meeting or ODAC as part of the review process. As before reported, Array is presently preparing for an Application Orientation Meeting or AOM with the FDA in September 2016, which it expects will include a discussion of the NDA package comprising clinical risk / benefit. The share price of ARRY attracts active investors, as stock price of week volatility recorded 6.28%. The stock is going forward to its 52-week low with 46.43% and lagging behind from its 52-week high price with -42.01%.
Smith & Wesson Holding Corporation (NASDAQ:SWHC) [Trend Analysis] plunged reacts as active mover, shares a loss -6.42% to traded at $27.68 and the percentage gap among open changing to regular change was -1.62%. The firm’s current ratio calculated as 2.70 for the most recent quarter. The firm past twelve months price to sales ratio was 2.38 and price to cash ratio remained 8.98. As far as the returns are concern, the return on equity was recorded as 37.30% and return on investment was 22.30% while its return on asset stayed at 16.80%. The firm has total debt to equity ratio measured as 0.57.